Research into T cell engagers (TCEs) is heating up, with over 100 preclinical projects and 65+ phase I and phase II clinical trials ongoing. Innovations in the field of TCEs will be highlighted at the upcoming 4th annual Cell Engager Summit. Taking place from May 24th-26th in Boston, MA, the Cell Engager Summit will host talks with speakers from academia to industry.
According to PharmaPhorum, “The 4th Annual Cell Engager Summit returns to bring you the latest on effectively targeting lymphocyte-restricted tumor-associated antigens to treat hematological malignancies, including CD19, CD20, BCMA, CD33, and CD123. Learn all there is to know about the immune cell engager landscape, including clinical achievements, potential response predictors, and novel immune cell-based engager therapeutic discoveries. “
Click here to read more and download the event guide.
(Source: PharmaPhorum, May 3rd, 2022)